This study is testing a ‘monoclonal antibody’ that may help to control the symptoms of SLE including the skin manifestations of lupus. A what? A monoclonal antibody! What’s that?
Monoclonal Antibodies (mAb) are heard of more often and have more uses, these days. But what are they? Remember, that antibodies are cells in the immune system which fight off invading organisms. Monoclonal antibodies are antibodies made by combining B lymphocytes with cancer-causing cells to the same end: to fight off invadng organisms. These cells are usually used to produce antibodies against the cancerous cells. Monoclonal antibodies are used instead of chemotherapy in patients with a form of bone cancer.
It was discovered that mAbs had uses in autoimmune diseases, like lupus, plaque psoriasis, rheumtoid arthritis to name a few. These are a few of the more common mAbs: Humira™, is a mAb, used for plaque psoriasis and Rheumatoid Arthritis. Rituxan™ is an mAb often used for lupus. Benlysta™ is an mAb often used for the treatment of SLE also. In fact, Benlysta™ was the first medication approved by the FDA for lupus treatment.
Unlike chemotherapy, which targets-well everthing, mAb’s targets specific structures (bacteria, viruses, cancer cells, etc-therefore there are fewer side effects to therapy with mAbs. Fewer side effects, more targeted medication, FDA-approved; what’s not to like?
Click here to be directed to the questionairre to see if you qualify for the clinical trial!
Hits : 247